

# ASX Release

---

Issued 30 October 2017

## Trading Update

Astra Zeneca recently advised pharmacies and all CSO pharmaceutical wholesalers that they intend to exclusively distribute a proportion of their products direct to Pharmacy effective from 1 November 2017.

The products identified currently represent approximately 1% of Sigma's total sales.

Sigma is actively reviewing a number of options to offset the earnings impact of this change including pharmacy trading terms.

More importantly, the CSO wholesaler industry body NPSA and the Pharmacy Guild are in consultation with the Government to ensure a sustainable medicine supply chain which includes mandatory availability of PBS products via CSO wholesalers. Further information is available at [www.npsa.org.au](http://www.npsa.org.au)

Sigma's guidance for FY2018 and FY2019 is unchanged.

**Contact:**

Gary Woodford  
Corporate Affairs Manager  
Sigma Healthcare Limited  
gary.woodford@sigmahealthcare.com.au  
0417 399 204 | 03 9215 9632